(2-cyclopentyl-6,7-dichloro-2-methyl-1-oxo-5-indanyloxy)acetic acid | 53108-00-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: (2-cyclopentyl-6,7-dichloro-2-methyl-1-oxo-5-indanyloxy)acetic acid
• 英文别名: (+)-[(6,7-dichloro-2-cyclopentyl-2,3-dihydro-2-methyl-1-oxo-1H-inden-5-yl)oxy]acetic acid；2-[(2-cyclopentyl-6,7-dichloro-2,3-dihydro-2-methyl-1-oxo-1H-inden-5-yl)oxy]acetic acid；indanyloxyacetic acid 94；indanyloxyacetic acid-94；(1-oxo-2-cyclopentyl-2-methyl-6,7-dichloro5-indanyloxy)-acetic acid；IAA-94；[(6,7-Dichloro-2-cyclopentyl-2-methyl-1-oxo-2,3-dihydro-1h-inden-5-yl)oxy]acetic acid；2-[(6,7-dichloro-2-cyclopentyl-2-methyl-1-oxo-3H-inden-5-yl)oxy]acetic acid
• CAS: 53108-00-2
• 化学式: C₁₇H₁₈Cl₂O₄
• 分子量: 357.234
• InChiKey: RNOJGTHBMJBOSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

制备方法与用途

(Rac)-甲基吲唑酮是一种强效的CLIC1通道阻断剂。

反应信息

• 作为反应物：
  描述：

  (2-cyclopentyl-6,7-dichloro-2-methyl-1-oxo-5-indanyloxy)acetic acid 生成 2-cyclopentyl-2-methyl-5-hydroxy-6,7-dichloro-1-indanone
  参考文献：
  名称：

  Treatment of brain injury due to gray matter edema with (indanyloxy)

  摘要：

  本发明涉及通过给予（indanyloxy）丁酸、其衍生物、类似物及其盐的治疗和预防因意外事故、缺血性中风、心脏骤停、呼吸停止、Reye综合症和脑积水导致的脑灰质和脊髓损伤。

  公开号：

  US04465850A1
• 作为产物：
  描述：

  2-cyclopentyl-2-methyl-5-hydroxy-6,7-dichloro-1-indanone 以75%的产率得到
  参考文献：
  名称：

  WOLTERSDORF O. W. JR.; SOLMS S. J. DE; SCHULTZ E. M.; CRAGOE E. J. JR., J. MED. CHEM. , 1977, 20, NO 11, 1400-1408

  摘要：

  DOI：

文献信息

• [EN] INDANONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] FACTEURS DE POTENTIALISATION D'INDANONE DE RÉCEPTEURS MÉTABOTROPIQUES DE GLUTAMATES
  申请人：MERCK & CO INC

  公开号：WO2006015158A1

  公开（公告）日：2006-02-09

  The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及一类潜在激活代谢型谷氨酸受体的化合物，包括mGluR2受体，这些化合物在治疗或预防与谷氨酸功能障碍相关的神经系统和精神疾病以及代谢型谷氨酸受体参与的疾病中具有用途。该发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗代谢型谷氨酸受体参与的疾病中的用途。
• [1-Hydroximino-2,2-disubstituted-5-indanyloxy-(or thio)]alkanoic acids
  申请人：Merck & Co., Inc.

  公开号：US03974212A1

  公开（公告）日：1976-08-10

  [1-Hydroximino-2,2-disubstituted-5-indanyloxy-(or thio)]alkanoic acids and their salt, ester, anhydride, amide and 5-tetrazolyl derivatives are disclosed. The products display a dual pharmaceutical utility in that they exhibit diuretic, saluretic and uricosuric activity. The acid products are prepared by treating a 1-oxo-2,2-disubstituted-5-indanyloxy(or thio)alkanoic acids or derivatives thereof with hydroxylamine in the presence of a base.

  1-羟基亚胺基-2,2-二取代-5-茚氧基（或硫代）烷酸及其盐、酯、酐、酰胺和5-四唑基衍生物已被披露。这些产品具有双重药用功能，因为它们表现出利尿、排盐和尿酸排泄活性。酸性产物是通过将1-氧代-2,2-二取代-5-茚氧（或硫代）烷酸或其衍生物与羟胺在碱的存在下处理而制备的。
• Treatment of gray matter edema
  申请人：Merck & Co., Inc.

  公开号：US04389417A1

  公开（公告）日：1983-06-21

  The invention relates to the treatment of gray matter edema in the brain or spinal chord by the administration of (indanyloxy)acetic acids, and analogs and salts thereof.

  本发明涉及通过给予（indanyloxy）乙酸及其类似物和盐来治疗脑或脊髓中的灰质水肿。
• Substituted-3-(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones
  申请人：Merck & Co., Inc.

  公开号：US04680414A1

  公开（公告）日：1987-07-14

  The invention relates to novel substituted-3-(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones, their analogs and their salts. These compounds are synthesized by methods selected from a number of synthetic routes depending on the particular structure, choice of intermediate or preferred reaction sequence. The compounds are useful for the treatment and prevention of injury to the brain and of edema due to head trauma, stroke (particularly ischemic), arrested breathing, cardiac arrest, Reye's syndrome, cerebral thrombosis, cerebral embolism, cerebral hemorrhage, cerebral tumors, encephalomyelitis, spinal cord injury, hydrocephalus, post-operative brain injury trauma, edema due to cerebral infections and various brain concussions.

  本发明涉及新型取代-3-(2,3-二氢-1H-茚-5-基)-4-羟基-1H-吡咯-2,5-二酮及其类似物和盐。这些化合物通过选择特定的结构、中间体或首选反应序列的方法进行合成。这些化合物可用于治疗和预防脑部损伤和水肿，如头部创伤、中风（特别是缺血性中风）、呼吸停止、心脏停搏、Reye综合征、脑血栓形成、脑栓塞、脑出血、脑肿瘤、脑炎、脊髓损伤、脑积水、术后脑损伤、由脑部感染引起的水肿和各种脑震荡。
• Dopamine analog amide
  申请人：——

  公开号：US20010056116A1

  公开（公告）日：2001-12-27

  The invention involves the formation of a prodrug from a fatty acid carrier and a neuroactive drug. The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. Once in the central nervous system, the prodrug is hydrolyzed into the fatty acid carrier and the drug to release the drug. In a preferred embodiment, the carrier is 4, 7, 10, 13, 16, 19 docosahexa-enoic acid and the drug is dopamine. Both are normal components of the central nervous system. The covalent bond between the drug and the carrier preferably is an amide bond, which bond may survive the conditions in the stomach. Thus, the prodrug may be ingested and will not be hydrolyzed completely into the carrier molecule and drug molecule in the stomach.

  该发明涉及使用脂肪酸载体和神经活性药物形成前药。该前药在胃和血液流动环境中稳定，并可通过口服递送。该前药容易穿过血脑屏障。一旦进入中枢神经系统，前药被水解成脂肪酸载体和药物以释放药物。在首选实施方式中，载体是4,7,10,13,16,19二十二碳六烯酸，药物是多巴胺。两者都是中枢神经系统的正常成分。药物和载体之间的共价键通常是酰胺键，这种键可以在胃的条件下存活。因此，前药可以被摄入，并且不会在胃中完全水解成载体分子和药物分子。